Concepedia

Carol E. Peña

CE

34

Publications

2.6K

Citations

24

H-Index

1996

Active since

Affiliations

Bayer (United States)(Current)

Bayer (Germany)

University of Pittsburgh

Institut Gustave Roussy

The University of Texas MD Anderson Cancer Center

Carol E. Peña is an author at Bayer (United States) specializing in medicine, oncology, and pathology.

ORCID

Top concepts

Publications per year

1996–2024

34

Publications

34

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

Josep M. Llovet, Carol E. Peña, Chetan Lathia et al. · Clinical Cancer Research · 2012 · 557 citations · Full text

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · Journal of Clinical Oncology · 2017 · 386 citations

, , +17

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Amita Patnaik, Leonard J. Appleman, Anthony W. Tolcher et al. · Annals of Oncology · 2016 · 229 citations · Full text

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Carol E. Peña, Chetan Lathia, Minghua Shan et al. · Clinical Cancer Research · 2010 · 172 citations

Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis

Ronald M. Bukowski, Timothy Eisen, Cezary Szczylik et al. · Journal of Clinical Oncology · 2007 · 131 citations

, , +20

Rows per page

1–5 of 34